The checkpoint Rad proteins Rad17, Rad9, Rad1, Hus1, ATR, and ATRIP become associated with chromatin in response to DNA damage caused by genotoxic agents and replication inhibitors, as well as during unperturbed DNA replication in S phase. Here we show that murine Rad17 is phosphorylated at two sites that were previously shown to be modi®ed in response to DNA damage, independent of DNA damage and ATM, in proliferating tissue. In contrast to studies with Xenopus laevis extracts but similar to observations in Schizosaccharomyces pombe, the level of chromatin-bound hRad17 remains relatively constant during the cell cycle and does not change signi®cantly in response to DNA damage or replication block. However, phosphorylated hRad17 preferentially associates with the sites of ongoing DNA replication and interacts with the DNA replication protein, DNA polymerase e. These results provide a link between the DNA damage checkpoint machinery and the replication apparatus and suggest that hRad17 may play a role in monitoring the progress of DNA replication via its interaction with DNA polymerase e.
INTRODUCTION
Damage to the genome, arising from replication errors and environmental factors, pose a grave threat to genomic stability and can ultimately lead to cancer formation. Cell cycle checkpoints prevent this damaged DNA from being replicated and passed on to future daughter cells (1, 2) . A group of six proteins called the checkpoint Rad proteins, ®rst identi®ed in Schizosaccharomyces pombe and Saccharomyces cerevisiae, mediate checkpoint activation, including the intra-S checkpoint and the S/M checkpoint, in response to DNA damage during DNA replication or incomplete replication, respectively (3, 4) . Human homologs of these checkpoint Rad proteins (hRad17, hRad9, hRad1, hHus1, ATRIP, and ATR) are required to activate cell cycle checkpoints through a signaling cascade to the downstream checkpoint effector Chk1 (5±11). Upon activation, Chk1 phosphorylates and thereby negatively regulates the phosphatase Cdc25 and activates the kinase Wee1 (12±16). Activation of Chk1 also results in the inactivation of Cdc2, which is required for the cell to progress through the G 2 /M checkpoint (17, 18) . In mice, this checkpoint-signaling cascade appears to be required for embryogenesis. Cells derived from early embryos of Atr ±/± -, Hus1 ±/± -and Chk1 ±/± -de®cient mice are sensitive to DNA damage, have an aberrant G 2 /M checkpoint and exhibit spontaneous genomic instability (8,19±23) .
Xenopus laevis egg extracts have been used to elucidate the role of checkpoint Rad proteins in the regulation of DNA replication and checkpoint activation during DNA synthesis. Initiation of DNA replication by the primase activity of DNA polymerase a is required for the chromatin association of X.laevis (Xl)ATR (24) . Immunodepletion of XlATR, even in untreated extracts, abrogates the phosphorylation of Chk1 and the subsequent S/M replication checkpoint, resulting in a shortened cell cycle (25, 26) . Additionally, XlHus1 and XlRad17 are required for the S/M replication checkpoint and checkpoints activated in response to DNA damage or replication inhibitors (27±29). Unlike the replicationdependent loading of XlRad17, a signi®cant portion of ®ssion yeast S.pombe (Sp)Rad17 is bound to the chromatin throughout the cell cycle (30) ; however, there is a dynamic change in the amount of chromatin-bound SpRad17 in response to different genotoxic agents. Exposure to replication inhibitors results in the release of SpRad17 from the chromatin (31), whereas treatment with DNA-damaging agents causes an increase in chromatin-associated SpRad17 (30) . Although these data suggest that the checkpoint Rad proteins function during S phase to monitor the progression of DNA replication and/or replication forks, it is not known how the checkpoint Rad proteins perform this monitoring function.
Rad17 is closely related to the ®ve replication factor C (RFC) subunits (32±35). The pentameric RFC complex loads proliferating cell nuclear antigen (PCNA) onto the DNA during replication. hRad17 replaces the large subunit of RFC, p140, in an alternative form of the clamp-loading complex that interacts with the PCNA-like heterotrimeric Rad9±Rad1± Hus1 (9-1-1) complex (36) . Recent biochemical studies with the homologous complexes isolated from budding yeast have demonstrated that the alternative RFC-like complex linked with checkpoint activation has clamp-loading activity (37) . In agreement with the functional interaction between the hRad17 clamp-loading complex and the 9-1-1 complex in vitro, DNA damage-dependent chromatin association of hRad9 requires hRad17 in vivo (7). Furthermore, phosphorylation of hRad17 by ATR on Ser635 and Ser645 in response to DNA damage and replication block stimulates the interaction between hRad17 and the 9-1-1 complex (38) . Interestingly, hRad17 is also phosphorylated on these same two serine residues during unperturbed S phase, suggesting a role for hRad17 during DNA replication (6) . In support of this idea, human cells engineered for conditional deletion of hRad17 alleles undergo endoreduplication after loss of hRad17 function (39) . Recent reports have demonstrated that the checkpoint Rad protein hRad9 interacts with TopBP1, a DNA polymerase e subunit, even in the absence of DNA damage (40) . Additionally, hRad9 was shown to interact with PCNA (41, 42) . These observations suggest that the checkpoint Rad proteins may monitor DNA replication by interacting with the DNA replication machinery.
As noted above, there are differences in the regulation of Rad17 subnuclear localization among different eukaryotes. Therefore, we have examined the behavior of mammalian Rad17 during S phase. Here we show that mammalian Rad17 is phosphorylated during unperturbed S phase in replicating tissue in a DNA damage-independent and ATMindependent manner. We demonstrate that the level of chromatin-associated hRad17 remains constant throughout the cell cycle, in response to genotoxic agents, and regardless of phosphorylation status. Finally, we show that phosphorylated hRad17 localizes to sites of DNA replication and interacts with the DNA replication machinery.
MATERIALS AND METHODS

Collection of murine tissues samples
One-month-old wild-type (Atm +/+ ) and ATM-de®cient (Atm ±/± ) mice were treated with 10 Gy ionizing radiation (IR) and then killed 1 h post-treatment. IR was performed using a 137 Cs g-irradiator (Shepherd) at 2.08 Gy/min. Tissues were collected and frozen in liquid nitrogen. Extracts were prepared by grinding frozen tissues prior to resuspension in lysis 250 buffer (50 mM Tris pH 7.4, 250 mM NaCl, 2 mM EDTA and 1.0% NP-40) supplemented with a cocktail of protease and phosphatase inhibitors containing 10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 100 mM sodium¯uoride, 1 mM sodium orthovanidate, 1 mM benzamide and 1 mM b-glycerophosphate. Proteins were separated by SDS± PAGE and transferred to PVDF membranes (Millipore). Membranes were incubated with the indicated antibodies and antigen±antibody complexes were detected with an enhanced chemiluminescence kit (Amersham).
Antibodies
Mouse a-hRad17 (31E9) monoclonal antibodies have been described previously (35) . Characterization of the rabbit ahRad17 phospho-speci®c polyclonal antibodies has been reported previously (6) . Mouse a-HA.11 (Babco), a-DNA polymerase e (93H3A) (NeoMarkers), a-PCNA (PC10) (Santa Cruz), a-Flag (M2) (Sigma) and a-Mek2 (Cell Signaling) were purchased from commercial sources. Rabbit a-Orc2 was a kind gift from Dr Bruce Stillman.
Generation of cell lines
MCF-7 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco) supplemented with 15% fetal calf serum (FCS) (Gibco) and 1 mg/ml insulin (Sigma). To generate tetracycline-inducible stable cell lines, MCF-7 cells were transfected with the doxycycline repressible plasmid pUHG 15-1 and selected in 1 mg/ml neomycin for 2 weeks. Regulation of protein expression in selected cells was determined by transient transfection with the reporter plasmid pTRE-2dGFP (Clontech) in the presence or absence of doxycycline. Cells expressing N-terminal HA-tagged hRad17 were generated by co-transfecting each construct, at a 10:1 ratio with pPuro (Stratagene), followed by selection in 500 ng/ml puromycin (Sigma). Stable MCF-7 clones expressing the wild-type or the phosphorylation site mutant of hRad17 were maintained in DMEM supplemented with 15% FCS, 1 mg/ml insulin, 400 mg/ml G-418 (Gibco), 100 ng/ml puromycin and 1 mg/ml doxycycline (Sigma). Expression of wild-type and phosphorylation site mutants of HA-hRad17 was induced by removing doxycycline from the medium for 72 h. Expression of recombinant protein was determined by immunoblotting. Synchronized and unsynchronized T24 cell lines and HeLa cell lines were cultured as previously described (6, 43) .
Fluorescence-activated cell sorting
The human bladder carcinoma T24 cells were density arrested and released as described previously (6, 43, 44) . After trypsinization, cells were harvested, washed with phosphatebuffered saline (PBS), resuspended in 70% ice-cold ethanol and then incubated at 4°C for 30 min. Cells were spun down, washed with PBS and resuspended in PBS containing 0.1% Triton X-100 and 200 mg/ml RNase A (Sigma) prior to incubation for 30 min at room temperature. Finally, cells were stained with 20 mg/ml propidium iodide and then analyzed using a FACScan (Becton-Dickinson).
DNA damage and replication inhibition
Hydroxyurea was added to cell culture medium at a ®nal concentration of 1 mM for 24 h, aphidicolin at a ®nal concentration of 5 mg/ml for 20 h and actinomycin D at a ®nal concentration of 1 mg/ml for 6 h. Cell extracts were prepared from mock-or IR-treated cells 1 h post-treatment.
inhibitors as above. Chromatin fractionation was performed using modi®cations to a previously described method (7, 44, 45) . Brie¯y, equal numbers of synchronized or treated cells were washed twice in ice-cold PBS followed by incubation in buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl, 0.34 M sucrose, 10% glycerol, 0.5% Triton X-100 and protease and phosphatase inhibitors) for 5 min. After low speed centrifugation, the supernatant cytoplasmic fraction (Cyto) was removed. The pellet containing nuclei was washed in buffer A and then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA and protease and phosphatase inhibitors). Soluble nuclear proteins (Nuc Sol) were separated from the chromatin fraction (Chr) by low speed centrifugation. The chromatin-enriched pellet was washed in buffer B and resuspended in 2Q SDS sample buffer and sonicated three times for 15 s.
Immuno¯uoresence T24 cells were seeded onto 12 mm glass coverslips that had been pre-coated for 30 min with 0.1% gelatin and prepared for immunostaining as described previously (46) . Brie¯y, cells were washed twice in cold PBS and then permeabilized by incubation in PBS containing 0.5% Triton X-100, 2 mM EDTA and 1% bovine serum albumin (BSA) for 15 min at 4°C. After washing with PBS, cells were ®xed in 100% methanol at ±20°C for 15 min. Cells were washed with PBS and then blocked by incubation with PBS containing 10% FCS for 2 h at room temperature. Antibodies were added and incubated in PBS containing 5% FCS for 2 h. Cells were washed ®ve times in Tris-buffered saline with Tween-20 (TBST) for 10 min and then incubated with goat a-mouse conjugated with¯uorescein isothiocyanate (Jackson Immunochemical), goat a-rabbit conjugated with rhodamine B isothiocyanate (Jackson Immunochemical) and 4¢,6-diamidino-2-phenylindole (DAPI) for 1.5 h. After washing in TBST, coverslips were mounted on slides using Immunon mountant.
For bromodeoxyuridine (BrdU) and hRad17 co-localization, T24 cells were incubated in medium supplemented with 10 mM BrdU for 15 min prior to ®xation. Cells were washed twice in cold PBS followed by permeabilization and ®xation as above. After treatment with 4 N HCl containing 0.2% Triton X-100 for 10 min, cells were washed with PBS, then incubated with 50 mM glycine for 5 min, washed once with PBS and then blocked in PBS containing 10% FCS for 2 h at room temperature. Finally, cells were incubated with mouse a-BrdU (Becton Dickinson) and rabbit a-hRad17-phosphoSer645 in PBS containing 5% FCS for 2 h and then visualized as described above.
Immunoprecipitation
Cell lysates were prepared in lysis 250 buffer containing ethidium bromide at a ®nal concentration of 20 mg/ml and supplemented with phosphatase and proteases inhibitors as above. The clari®ed lysates were incubated with the indicated antibodies followed by incubation with protein G±Sepharose beads for 2 h. Immunoprecipitates were washed four times in lysis 250 buffer and boiled in 2Q SDS sample buffer. Proteins were separated by SDS±PAGE and transferred to PVDF membranes (Millipore).
In vitro hRad17 and DNA polymerase e interaction The pGEX4T-3 plasmid expressing full-length hRad17 as a GST fusion protein has been described (6) . Digestion of this plasmid with EcoRV and SmaI followed by religation generated plasmid GST±hRad17 1±320 that encoded the N-terminal 320 residues of hRad17. Fragments of hRad17 cDNA encoding residues 319±670 and 491±670 were ampli®ed by PCR and then subcloned into pGEX4T-3 to generate plasmids GST±hRad17 319±670 and GST±hRad17 419±670 , which encode these C-terminal fragments of hRad17 as GST fusions proteins. GST fusion proteins were expressed and puri®ed according to the manufacturer's protocol (Amersham). Fulllength DNA polymerase e cDNA, a gift from Dr Stuart Linn, was used as a template to synthesize 35 S-labeled DNA polymerase e coupled by in vitro transcription±translation using the TNT T7 Quick Kit (Promega). For the GST pulldown assays, equal amounts of GST, GST±hRad17 or GST± hRad17 fragments bound to glutathione±Sepharose beads were incubated with labeled DNA polymerase e in 50 mM Tris (pH 7.4), 120 mM NaCl, 2 mM EDTA, 0.1% NP-40 and 10% BSA for 2 h at 4°C. After extensive washing, bound proteins were released from the beads by boiling in 2Q SDS sample buffer. Labeled DNA polymerase e was visualized bȳ uorography after SDS±PAGE. 
RESULTS
Mammalian Rad17 is phosphorylated in undamaged replicating tissue in an ATM-independent manner
We previously demonstrated that the two DNA damagedependent phosphorylation sites of hRad17, Ser635 and Ser645, are also phosphorylated at the start of DNA replication in cultured synchronized cells (6) . To demonstrate that these phosphorylation events were not caused by the synchronization protocol, we examined the phosphorylation status of murine Rad17 in replicating and non-replicating tissues. Phosphorylation on both Ser647 and Ser657 residues of Mus musculus (Mm)Rad17, corresponding to hRad17
Ser635 and Ser645, was observed in extracts from both undamaged and IR-treated testes (Fig. 1A) . In contrast to replicating tissue, the same two residues were phosphorylated only after DNA damage in quiescent lung tissue. Since the kinase activity of ATR increases in response to S phase (25) , and ATM and ATR are both involved in the activation of S phase-dependent checkpoints (47,48), we asked whether ATM in¯uences the phosphorylation of mammalian Rad17 in replicating tissues after IR. The absence of ATM had little effect on the phosphorylation of MmRad17 in the presence or absence of DNA damage in testes (Fig. 1B) . These results, coupled with our previous data demonstrating that ATM is not required for the ionizing irradiation-dependent phosphorylation of Rad17 in quiescent and cycling cells (6), indicates that mammalian Rad17 is normally phosphorylated during replication in an ATM-independent manner and suggests that hRad17 monitors the progression of DNA replication in unperturbed cells.
Chromatin-associated levels of hRad17 remain constant throughout the cell cycle and in response to DNA damage
Using a fractionation procedure ®rst described in the Stillman laboratory (45), we have examined whether the distribution of hRad17 between the nucleoplasmic and chromatin fractions changes either as a function of cell cycle progression or in response to DNA damage. In asynchronous cells, the majority of hRad17 is in the nucleoplasmic fraction, but an appreciable amount was present in the chromatin fraction ( Fig. 2A) . In agreement with data from the Elledge laboratory, the level of chromatin-associated hRad17 was not signi®cantly altered by DNA damage (7). To directly address whether hRad17 is shuttled on and off chromatin during the cell cycle, we density arrested, released and harvested human T24 cells at different phases of the cell cycle. The cell cycle distributions of these synchronized cells were determined by FACS analysis (Fig. 2B) . As expected, the replication protein PCNA associates with chromatin at the start of S phase. In contrast to the S phase-dependent chromatin association of PCNA, we observed that~35±45% of hRad17 is associated with chromatin throughout the cell cycle, as determined by densitometry (Fig. 2C and D) . Thus, the behavior of hRad17 is different from that of XlRad17 (28) , which associates with chromatin at the start of DNA replication, but similar to that of S.pombe, in which a fraction of Rad17 remains bound throughout the cell cycle (30) . Furthermore, DNA damage did not affect the amount of hRad17 localized to the chromatin in speci®c cell cycle phases (Fig. 2C and data not shown) . In contrast to the steady-state levels of chromatin-bound hRad17, there were signi®cant changes in the phosphorylation of chromatin-bound hRad17 during cell cycle progression and in response to DNA damage. hRad17 Ser635 and Ser645 became phosphorylated at the start of S phase in undamaged cells and in IR-treated G 1 cells (Fig. 2C ). These results demonstrate that a pool of hRad17 remains bound to the chromatin at all phases of the cell cycle and that the association of hRad17 with the chromatin is not regulated by DNA damage.
Replication inhibitors and phosphorylation status does not effect the chromatin association of hRad17
Next we wanted to determine if hRad17 disassociates from chromatin after treatment with replication inhibitors and, if so, whether phosphorylation of hRad17 is required for this release. To address these questions, we created a stable cell line expressing HA-tagged versions of the wild-type and a phosphorylation site mutant hRad17 from a tetracyclineregulated promoter. Unlike ®ssion yeast (31), the replication Chromatin association of recombinant phosphomutant HA-tagged hRad17 in response to DNA damage and replication block. Cells expressing HA-tagged hRad17 were mock-treated, treated with 1 mg/ml actinomycin D for 6 h, 5 mg/ml aphidicolin for 20 h or 10 Gy IR or 1 mM hydroxyurea for 24 h. Cells lysates were fractionated as in Figure 2 and subjected to immunoblotting using the indicated antibodies. Doxycycline-treated and untreated whole cell extracts served as a control for loading and expression of HA-hRad17.
inhibitors hydroxyurea, aphidicolin and actinomycin D did not disrupt the chromatin association of hRad17 ( Fig. 3A and B) . Furthermore, the identical behavior of the phosphorylation site mutant form of hRad17 indicates that phosphorylation of hRad17 is not required for either the initial association with chromatin or in maintaining the interaction between hRad17 and chromatin after DNA damage or replication block (Fig. 3A  and B) .
Chromatin-associated and phosphorylated hRad17 colocalizes to sites of DNA replication Since hRad17 is phosphorylated at the beginning of S phase, we examined whether phosphorylated hRad17 associates with the replication machinery or sites of DNA replication by immunocytochemistry. Prior to ®xation, we used a protein extraction method ®rst described in Aboussekhra et al. to remove cytoplasmic and soluble nuclear proteins (46) . Immunostaining of the ®xed T24 cells revealed that phosphorylated hRad17 is extraction resistant and co-localizes with sites of active DNA replication as determined by colocalization with a-BrdU and a-PCNA (Fig. 4A and B) . Thus, phosphorylated hRad17 is localized at the sites of ongoing DNA replication.
Human Rad17 interacts with the replication protein DNA polymerase e Since phosphorylated hRad17 co-localizes with sites of DNA replication, we examined whether the phosphorylated hRad17 associates with replication proteins. Using lysates from untreated and IR-treated cells, the catalytic subunit of DNA polymerase e was co-immunoprecipitated by the hRad17 phospho-speci®c antibody (Fig. 5A ). These antibodies have been extensively characterized and shown to exclusively recognize phosphorylated Rad17 (6) . In reciprocal experiments, phosphorylated hRad17 was immunoprecipitated by the a-DNA polymerase e antibody (Fig. 5A ). This appears to re¯ect a speci®c association between hRad17 and DNA polymerase e because a-Flag antibodies were unable to immunoprecipitate either DNA polymerase e or hRad17 and another replication protein, PCNA, was not co-immunoprecipitated by the hRad17 phospho-speci®c antibody (data not shown).
Next, we performed in vitro binding assays to determine if there is an interaction between these proteins. Full-length in vitro transcribed/translated DNA polymerase e interacted with GST±hRad17 but not GST alone (Fig. 5B) . To determine which region of hRad17 interacts with DNA polymerase e, we generated a GST±N-terminal fragment of hRad17 containing amino acids 1±320 and two GST±C-terminal fragments of hRad17 containing amino acids 319±670 and 419±670, respectively. Similar to the full-length GST±hRad17, both the N-terminal fragment of hRad17 1±320 and the large Cterminal fragment of hRad17 319±670 speci®cally interact with in vitro transcribed/translated DNA polymerase e (Fig. 5B) . In contrast, the small C-terminal fragment, encoding amino acids 419±670 of hRad17, did not interact with DNA polymerase e in vitro (Fig. 5B) . Together these results demonstrate that hRad17 associates with DNA polymerase e in cell extracts and suggests that this association is mediated by a direct interaction between DNA polymerase e and the N-and Cterminal regions of hRad17.
DISCUSSION
Although phosphorylation of hRad17 is required for DNA damage-induced checkpoint activation (6, 38) , the same residues are also phosphorylated in unperturbed S phase proliferating cells in vitro and in vivo (Fig. 1) (6) . This Extracts from mock-treated or irradiated HeLa cells were prepared as described in Materials and Methods. After immunoprecipitation with a-hRad17-phosphoSer645, a-DNA polymerase e or a-hRad17 antibodies, proteins in the immunoprecipitates were separated by SDS±PAGE and immunoblotted with a-hRad17-phosphoSer645 or a-DNA polymerase e antibodies. Whole cell extracts served as a positive control and immunoprecipitation with a-Flag antibodies served as a negative control. (B) Interaction between 35 S-labeled in vitro transcribed/translated DNA polymerase e and GST±hRad17. In vitro transcribed/translated DNA polymerase e was incubated with equal amounts of GST±full-length hRad17±, GST±N-hRad17 1±320 ±, GST±C-hRad17 319±670 ± or GST± hRad17 419±670 ±Sepharose beads and then separated by SDS±PAGE followed by¯uorography. One-tenth load of 35 S-labeled in vitro transcribed/translated DNA polymerase e served as a control. phosphorylation pattern is similar to the S phase-dependent checkpoint-signaling pathway observed in both human and X.laevis, in which Chk1 is also phosphorylated by ATR in the absence of exogenous DNA damage during DNA replication (25, 49) . The simplest explanation for these signaling events is that low levels of DNA damage occur during DNA replication and activate the cell cycle checkpoint-signaling cascade. However, DNA damage-dependent checkpoint activation appears unlikely, as hRad9 does not exhibit the characteristic DNA damage-induced mobility shift caused by phosphorylation in the absence of exogenous DNA-damaging agents during S phase (42, 50) . Thus, it appears that hRad17 phosphorylation occurs as a normal consequence of DNA replication and may re¯ect the participation of hRad17 in a function associated with DNA replication, in addition to the DNA damage-induced checkpoint pathway.
Here we have shown that~40% of hRad17 is constitutively chromatin-associated independent of cell cycle phase or the start of DNA replication. This behavior is similar to that observed in S.pombe but differs from the observations in X.laevis (28, 30) . Several lines of evidence indicate that phosphorylation of hRad17 does not affect its chromatin association. First, the amount of chromatin-associated hRad17 remains relatively unchanged throughout the cell cycle or in response to genotoxic stress. Second, both the wild-type and phosphorylation site mutant forms of hRad17 associate with chromatin before and after treatment with genotoxic agents (Fig. 3) . This further demonstrates that ATR-dependent phosphorylation is not required for Rad17 association with chromatin and is consistent with the observation that the lack of DNA damage-and replication block-induced phosphorylation of hRad17 in Hus1 ±/± cells does not affect the chromatin association of hRad17 (7) .
Interestingly, we observed that phosphorylated hRad17 colocalizes to sites of ongoing DNA replication as determined by co-immunostaining with a-BrdU and a-PCNA antibodies ( Fig. 4A and B) . These data, coupled with the recent ®nding of endoreduplication in the absence of hRad17, strongly support the notion that hRad17 has a key role in the regulation of DNA replication and suggest that chromatin-associated, phosphorylated hRad17 may serve as a sensor of DNA replication progression (39) . In support of this replication surveillance model, we found that the phosphorylated form of hRad17 associates with DNA polymerase e, a DNA replication enzyme that has also been implicated in cell cycle checkpoints (51, 52) . Although it is not known whether hRad17 phosphorylation regulates its interaction with DNA polymerase e, this interaction provides a physical link between checkpoint and DNA replication proteins. In addition to our results linking DNA polymerase e with the hRad17 clamp-loading complex, there is a conserved and direct interaction between TopBP1 in humans (Dpb11 in budding yeast), a subunit of DNA polymerase e and hRad9 (Ddc1 in budding yeast) that occurs in the absence of DNA damage (40, 53) . Thus, DNA polymerase e interacts with both the checkpoint clamp-loader and the checkpoint clamp complex, providing a possible molecular mechanism for the proposed checkpoint activities of DNA polymerase e and the participation of hRad17 in the regulation of DNA replication.
Even though phosphorylated hRad17 interacts with the replication machinery and localizes to sites of DNA replication during unperturbed S phase, the possibility remains that hRad17 may only localize to sites of stalled forks or where DNA damage is sensed during S phase, because not all aphospho-hRad17 and a-BrdU or a-PCNA foci overlap ( Fig. 4A and B) . A possible role for phosphorylated hRad17 is that it may monitor replication fork stability and sense replication blocks during unperturbed replication. Alternatively, it may inhibit DNA reduplication, likely through its interactions with components of the replication machinery. Although the effect of hRad17 phosphorylation on DNA replication remains to be elucidated, our research provides evidence that phosphorylated hRad17 links the checkpoint Rad proteins and the replication machinery.
